| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0065-2571(00)00011-X |
| P698 | PubMed publication ID | 11384742 |
| P2093 | author name string | Johnson MR | |
| Diasio RB | |||
| P2860 | cites work | Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity | Q24561644 |
| Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity | Q33327925 | ||
| Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency | Q33539839 | ||
| Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity | Q73764482 | ||
| P304 | page(s) | 151-157 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Advances in Enzyme Regulation | Q15756443 |
| P1476 | title | Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil | |
| P478 | volume | 41 |
| Q36317002 | Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. |
| Q46502244 | Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy |
| Q46225918 | Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? |
| Q33432892 | Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency |
| Q34342248 | Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk |
| Q36927562 | DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS. |
| Q57812660 | DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis |
| Q47768032 | DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update |
| Q81234951 | DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients |
| Q36936972 | Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience |
| Q57798406 | Dihydropyrimidine Dehydrogenase Deficiency: Homozygosity for an Extremely Rare Variant in DPYD due to Uniparental Isodisomy of Chromosome 1 |
| Q34216563 | Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity |
| Q37595951 | Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity |
| Q92471072 | Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity |
| Q90486073 | Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers |
| Q34642023 | Gastric cancer: Classification, histology and application of molecular pathology |
| Q50073098 | Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. |
| Q36486034 | How may anticancer chemotherapy with fluorouracil be individualised? |
| Q46502211 | Identification of two novel mutations C79X and R235Q in the dihydropyrimidine dehydrogenase gene in a patient presenting with hematuria |
| Q90151718 | Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5-FU Chemotherapy in a Saudi Patient |
| Q34775315 | Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. |
| Q45117158 | Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics |
| Q34134768 | Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity |
| Q41008100 | Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine |
| Q38866416 | KU32 prevents 5-fluorouracil induced cognitive impairment |
| Q34210342 | LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients |
| Q48250453 | Life-Threatening Reaction with Topical 5-Fluorouracil. |
| Q43053804 | Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. |
| Q35610513 | Pharmacogenomics and breast cancer |
| Q34612932 | Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes |
| Q46502256 | Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene |
| Q40234339 | Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity |
| Q53515176 | Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity. |
| Q36745681 | Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy |
| Q47139930 | Reversible severe fatty liver induced by capecitabine: A case report |
| Q40068183 | Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity |
| Q28301967 | Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question |
| Q46633436 | Severe 5-fluorouracil induced toxicity associated with dihydropyrimidine dehydrogenase deficiency |
| Q46835935 | TYMS and DPYD polymorphisms in a Turkish population |
| Q37784574 | The role of Sp1 and Sp3 in normal and cancer cell biology |
| Q38842633 | Therapeutic drug monitoring of 5-fluorouracil. |
| Q38565029 | Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score |
| Q37475866 | Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency |
| Q37425429 | XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center |
| Q37637668 | microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites |
Search more.